PAVES

Pegfilgrastim anti-vascular endothelial growth factor (VEGF) evaluation · Amgen

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PAVES, covering 2014-01-07 to 2014-01-07. Get the full timeline:

Most recent: Clinical Trial Update: PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study [Phase 3]